September 12-15, 2026
COEX Convention & Exhibition Center
Seoul, Republic of South Korea
Booth #813
Showcasing our Latest Innovations at WCLC 2026
Heading to Seoul this month for World Conference on Lung Cancer 2026?
We’ll meet you there: visit us at Booth #813 to discover the latest innovations in precision medicine and learn how Caris provides the high-quality molecular insights that help physicians make more informed treatment decisions throughout the cancer care journey.
Presenting New Caris Life Sciences Research at WCLC
Caris and collaborators from leading cancer centers — including those within the Caris Precision Oncology Alliance® (POA®) — will collectively present four Posters, one Poster Tour and one Mini Oral at WCLC 2026.
Schedule a Meeting
Products at a glance
Caris Assure
Whole Exome and Whole Transcriptome Sequencing from blood. This revolutionary, pan-cancer assay utilizes a novel circulating Nucleic Acid Sequencing (cNAS) approach. With deep molecular insights from a minimally invasive blood sample, Caris Assure™ delivers uncompromising reliability and performance to inform personalized treatment decisions to help improve patient outcomes.
MI Profile
MI Profile™ comprehensive testing delivers whole exome sequencing (WES – DNA) and whole transcriptome sequencing (WTS – RNA) for 23,000+ genes, as well as protein analysis and AI-predictive algorithms. The test is designed to reveal a complete molecular blueprint that can guide more precise and individualized treatment decisions that help improve patient outcomes.
Caris Molecular AI
With one of the largest, multi-modal databases of combined molecular and clinical outcomes data in the world, Caris applies highly sophisticated AI bioinformatics and machine learning capabilities on this massive database to create novel, clinically relevant solutions to classify cancer at the molecular level and predict patient response in ways never before possible.
Discover
More
Personalized Treatment Starts Here
Understanding cancer at the molecular level can lead to better treatment options. Caris molecular profiling includes whole exome and whole transcriptome sequencing of tissue and blood, plus protein analysis and other testing options for tissue specimens. Paired with molecular AI tools, Caris comprehensive molecular profiling is focused on helping cancer patients today and tomorrow.
Expert Scientific and Clinical Support
Caris’ healthcare provider services help put precision medicine into practice. Deep molecular insights enable physicians to navigate among therapies with potential benefit, identify therapies that may not have been considered, determine drugs unlikely to provide benefit (avoiding unnecessary toxicities and costs) and match patients to clinical trials.